[Arterial hypertension in old age with the focus on 80]

Dhayana Dallmeier1,2, Michael D Denkinger3,4

  • 1Geriatrie der Universität Ulm, AGAPLESION Bethesda Klinik, Zollernring 26, 89073, Ulm, Deutschland.

Insights

High blood pressure in older adults increases risks for stroke and heart failure. Guidelines recommend tailored treatment targets, often below 150/70 mmHg, considering frailty and other conditions.

Area of Science:

  • Gerontology
  • Cardiology
  • Internal Medicine

Background:

  • Untreated hypertension in older adults elevates risks for secondary conditions like stroke, myocardial infarction, and heart failure.
  • Current guidelines offer varying treatment targets based on age and frailty, necessitating careful consideration.

Purpose of the Study:

  • To review and synthesize current guidelines for managing hypertension in the elderly.
  • To provide recommendations for individualized treatment targets and medication selection in older adults with arterial hypertension.

Main Methods:

  • Literature review of current European guidelines on hypertension management in older adults.
  • Analysis of treatment recommendations for different frailty levels and age groups.
  • Consideration of polypharmacy and multimorbidity in treatment selection.

Main Results:

  • For slightly frail individuals up to 80 years, a target systolic blood pressure of 130-139 mmHg is recommended.
  • For those over 80, the same target is suggested, but treatment initiation is advised at ≥160 mmHg systolic.
  • For physically disabled or very frail individuals, a tailored approach with a target systolic value <150 mmHg (but not below 130/70 mmHg) is recommended.

Conclusions:

  • Arterial hypertension in old age can often be managed effectively following guidelines, with individualized approaches for frail patients.
  • Careful selection of antihypertensive medications is crucial, considering polypharmacy and potential drug interactions.
  • Treatment should be adapted based on patient tolerance and specific clinical circumstances.

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
605
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
467
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
509
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
619
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
534
Aging01:26

Aging

Aging is a complex biological phenomenon influenced by various processes that affect cellular and systemic functions. Several prominent theories attempt to explain its mechanisms, highlighting cellular limitations, oxidative damage, and hormonal changes as central factors in aging.
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
703